RxDoctor Payments Data

Abbas Rizvi, DO

Geriatric Medicine · Chicago, ILNPI 1285126656

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by EMD Serono, Inc. at 52.7% of the total. Reporting peaked in 2022 at $753 and has fallen 81.2% since, to $141 in 2025.

$1,430in general payments, 2019–2025

Across 11 payments — averaging $129.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$753
  • AbbVie$183
  • Johnson & Johnson$120
  • Abbott$104
  • Neurocrine Biosciences, Inc.$91
  • Amgen$79
  • plus $99 from 2 others

What the payments were for

  • Speaking & faculty fees$75353%
  • Food & beverage$66947%
  • Education$71%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,430 in reported general payments places this provider in the 85th percentile of 147 geriatric medicine providers in Illinois.

See all geriatric medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$89,718
Medicare patients
343
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$62,935
JardianceEmpagliflozin62$29,110
TrulicityDulaglutide25$21,554
FarxigaDapagliflozin Propanediol33$17,746
MyrbetriqMirabegron42$16,641
OzempicSemaglutide15$14,173
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,987
LinzessLinaclotide12$6,765
TradjentaLinagliptin13$6,398
Incruse ElliptaUmeclidinium Bromide13$6,342
Lidocaine36$4,071
Atorvastatin Calcium378$3,736
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,329
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$2,136
Gabapentin207$1,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$62,935114 claims
AbbVieLinzess$183$6,76512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 147 geriatric medicine providers in Illinois.

Other geriatric medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →